Tandem Diabetes Care (TNDM) Gains from Investment Securities (2013 - 2022)
Tandem Diabetes Care (TNDM) posted Gains from Investment Securities of -$44000.0 for Q4 2022, down 266.67% on a QoQ basis from -$12000.0 in Q3 2022, and down 237.5% year-over-year from $32000.0 in Q4 2021.
Tandem Diabetes Care (TNDM) Gains from Investment Securities (2013 - 2022) Analysis & Trends
Tandem Diabetes Care's Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$44000.0 for Q4 2022.
- Quarterly Gains from Investment Securities fell 237.5% year-over-year to -$44000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$147000.0 (down 110.61% YoY) and the FY2022 annual result came in at -$147000.0, down 110.61% from the prior year.
- Gains from Investment Securities was -$44000.0 for Q4 2022 at Tandem Diabetes Care, down from -$12000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $42.5 million in Q2 2018 and bottomed at -$2.8 million in Q4 2020.
- A 5-year average of $4.8 million and a median of $332000.0 in 2021 frame the typical range for Gains from Investment Securities.
- Peak annual rise in Gains from Investment Securities reached 3281.13% in 2020, while the deepest fall reached 1347.35% in 2020.
- Tandem Diabetes Care's Gains from Investment Securities stood at -$2.5 million in 2018, then soared by 108.87% to $226000.0 in 2019, then sank by 1347.35% to -$2.8 million in 2020, then surged by 101.14% to $32000.0 in 2021, then slumped by 237.5% to -$44000.0 in 2022.
- Business Quant data shows TNDM's Gains from Investment Securities at -$44000.0 in Q4 2022, -$12000.0 in Q3 2022, and -$57000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.17 Bn | 597.96 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -44,000.00 |
| Dec 31, 2022 | -44,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Mar 31, 2022 | -34,000.00 |
| Mar 31, 2022 | -34,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Jun 30, 2021 | 272,000.00 |
| Jun 30, 2021 | 272,000.00 |
| Mar 31, 2021 | 690,000.00 |
| Mar 31, 2021 | 690,000.00 |
| Dec 31, 2020 | -2.82 Mn |
| Dec 31, 2020 | -2.82 Mn |
| Sep 30, 2020 | 3.65 Mn |
| Sep 30, 2020 | 3.65 Mn |